Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028. The ...

Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised one of the biggest venture rounds for a biotechnology company so far this year. The company on ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Keytruda's sBLA for LA-HNSCC treatment is under FDA priority review, with a decision expected by June 23. The KEYNOTE-689 trial showed significant improvements in event-free survival and major ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for Keytruda (pembrolizumab) for a new indication.

Pfiz­er wants a piece of the show­down with the world’s biggest med­i­cine. The New York phar­ma gi­ant — fac­ing an ac­tivist in­vestor, shed­ding mul­ti­ple parts of … ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs).